| Literature DB >> 23198136 |
Roelie J Hempel1, Julian F Thayer, Christian H Röder, Hugo G van Steenis, Nico J M van Beveren, Joke H M Tulen.
Abstract
Previous research investigating the emotion recognition ability in patients with schizophrenia has mainly focused on the recognition of facial expressions. To broaden our understanding of emotional processes in patients with schizophrenia, this study aimed to investigate whether these patients experience and process other emotionally evocative stimuli differently from healthy participants. To investigate this, we measured the cardiac and subjective responses of 33 male patients (9 with and 24 without antipsychotic medication) and 40 male control subjects to emotion-eliciting pictures. Cardiac responses were chosen as an outcome measure because previous research has indicated that these are linked with attentional and emotional processes and provide a more objective measure than self-report measures alone. The differences in cardiac responses between patients and controls were limited to medicated patients: only the medicated patients showed significantly decreased cardiac orienting responses compared with control subjects, regardless of picture contents. These results indicate that medicated patients directed less attention towards emotion-eliciting pictures than controls. Decreased attentional resources while processing emotional evocative stimuli could lead to incorrect appraisals of the environment and may have detrimental emotional and social consequences, contributing to chronic stress levels and an increased risk for cardiovascular disease.Entities:
Year: 2012 PMID: 23198136 PMCID: PMC3502797 DOI: 10.1155/2012/858562
Source DB: PubMed Journal: Cardiovasc Psychiatry Neurol ISSN: 2090-0171
Demographic characteristics of the patient and control groups.
| Medicated patients ( | Antipsychotic-free patients ( | Controls ( | |
|---|---|---|---|
| Age (mean ± Sd) | 22 ± 4 | 21 ± 6 | 23 ± 4 |
| Smokers (Yes/No)a | 20/4 | 7/2 | 8/32 |
| Duration of illness (months ± Sd)b | 16 ± 19 | 3 ± 3 | |
| Duration of current medication use (weeks ± Sd) | 4 ± 4 | ||
| PANSSc (mean ± Sd) | |||
| Positive symptoms | 17 ± 6 | 23 ± 6 | |
| Negative symptoms | 15 ± 5 | 21 ± 5 | |
| General psychopathology | 33 ± 9 | 43 ± 12 | |
|
| |||
| Total | 65 ± 16 | 87 ± 14 | |
PANSS: positive and negative syndrome scale; Sd: standard deviation.
aThere were significantly more smokers in both patient groups than in the control group (χ ² = 27.78, P < 0.001).
b The duration of illness was significantly shorter in antipsychotic-free versus medicated patients (t[25.96] = 3.3, P < 0.01).
cAntipsychotic-free patients had higher PANSS scores for all subscales than medicated patients (positive: t[28] = 2.4, P < 0.05; negative t[28] = 2.6, P < 0.05; general psychopathology t[28] = 2.5, P < 0.05; total score t[28] = 3.5, P < 0.01).
Mean dosages and duration of current antipsychotic treatment of the patient group.
| Antipsychotic |
| Mean dosage (mg) ± Sd | Comedication |
|---|---|---|---|
| No Antipsychotic | 9 | Lorazepam ( | |
| Olanzapine | 8 | 16.3 ± 6.9 | Lorazepam ( |
| Oxazepam ( | |||
| Risperidone | 6 | 3.0 ± 0.8 | Lorazepam ( |
| Oxazepam ( | |||
| Haloperidol | 4 | 2.8 ± 1.5 | Lorazepam ( |
| Clozapine | 4 | 300.0 ± 81.6 | Lorazepam ( |
| Quetiapine | 2 | 450.0 ± 212.13 | — |
Sd: standard deviation.
Profile of mood states scores per group.
| Medicated patients ( | Antipsychotic-free patients ( | Controls ( | |
|---|---|---|---|
| POMS mean ± Sd (range) | |||
| Depression | 7 ± 7 (0–22)* | 8 ± 9 (0–28)* | 1 ± 2 (0–6) |
| Fatigue | 6 ± 6 (0–18) | 8 ± 5 (1–15)* | 3 ± 3 (0–11) |
| Tension | 6 ± 5 (0–16)* | 6 ± 4 (0–12)* | 2 ± 2 (0–9) |
| Anger | 5 ± 5 (0–17)* | 7 ± 5 (0–16)* | 1 ± 2 (0–10) |
| Vigour | 11 ± 5 (2–18) | 7 ± 5 (0–13)* | 12 ± 3 (5-18) |
| TMD | 12 ± 20 (−15–60)* | 21 ± 22 (2–68)* | −5 ± 7 (−14–14) |
Sd: standard deviation; TMD: total mood disturbance; *significant difference compared to controls, P < 0.01.
Beta coefficients of the HLM for cardiac responses to emotion-eliciting pictures in medication free patients, medicated patients, and healthy control subjects.
| Factor | Comparison between GroAFPs | Comparison between picture types | Beta coefficient | Standard error |
|
|---|---|---|---|---|---|
| Constant | −0.13 | 1.11 | −0.12 | ||
| AFP versus C | −0.88 | 0.43 |
| ||
| Group | MP versus C | 1.60 | 0.36 |
| |
| MP versus AFP | 2.51 | 0.45 |
| ||
| Neg. versus Neu. | −2.12 | 0.24 | − | ||
| Picture type | Pos. versus Neu. | −1.79 | 0.24 | − | |
| Pos. versus Neg. | 0.33 | 0.24 | 1.37 | ||
| Time1 | −5.63 | 1.72 | − | ||
| Time2 | −0.03 | 1.72 | −0.02 | ||
| AFP versus C | Neg. versus Neu. | 0.59 | 0.56 | 1.05 | |
| MP versus C | Neg. versus Neu. | 1.54 | 0.40 |
| |
| MP versus AFP | Neg. versus Neu. | 0.92 | 0.60 | 1.54 | |
| AFP versus C | Pos. versus Neu. | 1.65 | 0.56 |
| |
| Group × Picture Type | MP versus C | Pos. versus Neu. | 0.69 | 0.40 | 1.72 |
| MP versus AFP | Pos. versus Neu. | −1.02 | 0.60 | −1.71 | |
| AFP versus C | Pos. versus Neg. | 1.06 | 0.56 | 1.89 | |
| MP versus C | Pos. versus Neg. | −0.86 | 0.40 | − | |
| MP versus AFP | Pos. versus Neg. | −1.92 | 0.60 | − | |
| AFP versus C | −0.60 | 0.83 | −0.72 | ||
| Group × Time1 | MP versus C | 1.85 | 0.64 |
| |
| MP versus AFP | 2.46 | 0.91 |
| ||
| AFP versus C | −0.69 | 0.83 | −0.83 | ||
| Group × Time2 | MP versus C | −1.00 | 0.64 | −1.57 | |
| MP versus AFP | −0.30 | 0.91 | −0.33 | ||
| Neg. versus Neu. | −3.15 | 0.65 | − | ||
| Picture Type × Time | Pos. versus Neu. | −2.26 | 0.65 | − | |
| Pos. versus Neg. | 0.90 | 0.65 | 1.38 | ||
| Neg. versus Neu. | 0.26 | 0.65 | 0.40 | ||
| Picture Type × Time | Pos. versus Neu. | 0.37 | 0.65 | 0.56 | |
| Pos. versus Neg. | 0.11 | 0.65 | 0.17 | ||
| Age | 0.10 | 0.02 |
| ||
| Medication duration | −0.17 | 0.03 | − | ||
| Illness duration | −0.02 | 0.01 | − | ||
| HR baseline | −0.03 | 0.01 | − | ||
| Ln(HRV HF) | −0.09 | 0.08 | −1.09 | ||
| Ln(HRV_HF) × Time1 | 0.82 | 0.23 |
| ||
| Ln(HRV_HF) × Time2 | 0.18 | 0.23 | 0.79 | ||
| POMS TMD score | 0.01 | 0.01 |
|
*Numbers expressed in bold indicate significant effects at the 0.05 level.
HR: heart rate; Ln(HF-HRV): natural logarithm of high frequency heart rate variability; POMS: profile of mood states; TMD: total mood disturbance;
AFP: antipsychotic-free patients; C: control; MP: medicated patients; Neg: negative pictures; Neu: neutral pictures; Pos: positive pictures.
Figure 1Time series of mean cardiac responses to negative, neutral, and positive picture stimuli in (a) antipsychotic-free patients, (b) medicated patients, and (c) healthy control participants during the 6 seconds of picture presentation.
Figure 2(a) Pleasure and (b) Arousal ratings of antipsychotic-free patients, medicated patients, and healthy control subjects for positive, neutral, and negative pictures.